Shares of Moderna fell to $151.01 during today's evening trading session. Despite the -2.4% change, the Large-Cap Biotechnology company still trades 6.2% above its average analyst target price of $142.2. So there may be further downside for the Biotechnology stock. Moderna has target prices ranging from $62.0 to $310.0 per share, and its average rating is buy.
Moderna has an average level of shares sold short, at 7.4% of its total share float. The stock's short ratio (also called days to cover) is 6.26. The company's insiders own 9.58% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 73.4% of Moderna's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Baillie Gifford and Company | 12% | 44,655,817 | $6,743,474,679 |
| 2024-03-31 | Vanguard Group Inc | 10% | 39,036,872 | $5,894,957,826 |
| 2024-03-31 | Blackrock Inc. | 7% | 25,395,878 | $3,835,031,397 |
| 2024-03-31 | State Street Corporation | 4% | 14,452,035 | $2,182,401,725 |
| 2024-03-31 | FMR, LLC | 4% | 13,599,837 | $2,053,711,310 |
| 2024-03-31 | Flagship Pioneering Inc. | 3% | 9,666,038 | $1,459,668,345 |
| 2024-03-31 | Theleme Partners LLP | 2% | 7,321,797 | $1,105,664,524 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 6,750,479 | $1,019,389,796 |
| 2024-03-31 | Wellington Management Group, LLP | 1% | 5,604,703 | $846,366,169 |
| 2024-03-31 | Morgan Stanley | 1% | 5,493,965 | $829,643,624 |
